Arvinas, Inc. announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer.
The presentation highlighted ARV-806's differentiated profile based on degradation potency, antiproliferative activity, and induction of cancer cell death. ARV-806 is designed to target both the ON and OFF forms of KRAS G12D, which is the most common mutation of the KRAS protein, addressing a high unmet need in solid tumors.
These data underscore the differentiation of ARV-806 from other G12D targeting agents in development and support its best-in-class potential for KRAS G12D mutated cancers. The sustained pharmacodynamic activity observed in preclinical models also supports the potential for intermittent clinical dosing, and ARV-806 is currently being evaluated in a Phase 1 clinical trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.